Johnson & Johnson (NYSE:JNJ) Shares Sold by Tandem Investment Advisors Inc.

Tandem Investment Advisors Inc. trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 1.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 477,169 shares of the company’s stock after selling 7,962 shares during the quarter. Johnson & Johnson makes up 3.0% of Tandem Investment Advisors Inc.’s holdings, making the stock its 13th largest holding. Tandem Investment Advisors Inc.’s holdings in Johnson & Johnson were worth $74,791,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of JNJ. Bond & Devick Financial Network Inc. grew its holdings in shares of Johnson & Johnson by 6.4% during the third quarter. Bond & Devick Financial Network Inc. now owns 6,531 shares of the company’s stock valued at $1,017,000 after buying an additional 393 shares in the last quarter. Worth Financial Advisory Group LLC grew its stake in Johnson & Johnson by 4.9% in the third quarter. Worth Financial Advisory Group LLC now owns 11,537 shares of the company’s stock valued at $1,797,000 after purchasing an additional 542 shares in the last quarter. Ritholtz Wealth Management grew its stake in Johnson & Johnson by 90.9% in the third quarter. Ritholtz Wealth Management now owns 41,394 shares of the company’s stock valued at $6,447,000 after purchasing an additional 19,714 shares in the last quarter. Arkadios Wealth Advisors grew its stake in Johnson & Johnson by 54.3% in the third quarter. Arkadios Wealth Advisors now owns 71,925 shares of the company’s stock valued at $11,202,000 after purchasing an additional 25,298 shares in the last quarter. Finally, Venture Visionary Partners LLC grew its stake in Johnson & Johnson by 0.4% in the third quarter. Venture Visionary Partners LLC now owns 99,877 shares of the company’s stock valued at $15,558,000 after purchasing an additional 373 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

NYSE JNJ opened at $149.56 on Wednesday. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $175.97. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16. The stock has a market capitalization of $360.41 billion, a PE ratio of 9.32, a P/E/G ratio of 2.44 and a beta of 0.53. The stock has a 50-day simple moving average of $155.83 and a 200 day simple moving average of $155.51.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.43% and a net margin of 45.26%. The business had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. During the same quarter in the previous year, the firm earned $2.68 EPS. The firm’s revenue was up 2.3% compared to the same quarter last year. Research analysts anticipate that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be given a $1.24 dividend. The ex-dividend date is Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.32%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

Analysts Set New Price Targets

JNJ has been the topic of a number of recent research reports. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Raymond James boosted their target price on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Monday, April 15th. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price target for the stock from $169.00 to $170.00 in a research report on Thursday, April 18th. Finally, Morgan Stanley reduced their price target on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 17th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $175.86.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.